Replies to post #736015 on NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

Even cancer patients have not been able to get TICE BCG on occasion, and you just brush off small companies and research facilities having to go without and find funds for another version (not approved or manufactured here) to go elsewhere and start over with something else, and why would a company pursue an ingredient in yet another trial when the manufacturer hasn’t completed a new facility since 2012 and doesn’t intend to until 2026, and then only slowly.

For example:

August 2019

Nonrandom’ availability
Despite Merck’s practice of allocating [Tice BCG] based on historical purchasing, patterns of shortages have not emerged. In some cases, large academic centers are experiencing shortages, whereas others have plenty of BCG in stock. — https://www.healio.com/news/hematology-oncology/20190805/bcg-a-realworld-example-of-health-care-rationing

[iclight]

I hear the Gen 2 has twice the ORR! Still zero, but 2x0.